^
Association details:
| Biomarker: | PBRM1 underexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor
Published date:
11/13/2019
Excerpt:
We identified 116 mRCC patients who were administered sunitinib or sorafenib...Patients with low PBRM1 expression had significantly shorter median PFS (9 vs 26 months, P < 0.001) and OS (21 vs 44 months, P < 0.001) than those with high expression. The expression of PBRM1 could be a significant prognostic factor for mRCC patients treated with targeted therapy...
DOI:
10.1007/s10147-019-01564-1
